Genfit

GNFT.PA

Loos, France· Est. 1999

genfit.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

GNFT.PA · Stock Price

EUR 8.40+8.40 (+0.00%)

Market Cap: $502.2M

Historical price data

Market Cap: $502.2MPipeline: 22 drugs (1 Phase 3)Founded: 1999Employees: 100-250HQ: Loos, France

Sector Ranking#220 in Small Molecule Drugs #78 in Diagnostics & Precision Medicine

Overview

Founded in 1999, Genfit has established itself as a key player in liver disease R&D, leveraging deep expertise in nuclear receptor biology to develop therapeutics and diagnostics. Its strategy is validated by the Phase 3 success of elafibranor in PBC and the commercial launch of its NIS4® diagnostic. The company is now executing a dual-track strategy of advancing its late-stage asset towards regulatory approval while building a commercial diagnostics business.

Metabolic DiseasesLiver Diseases

Technology Platform

A proprietary platform centered on nuclear receptor (PPAR) biology, integrated with multi-omics and biomarker discovery to develop therapeutics and non-invasive diagnostics for liver diseases.

Pipeline

22 drugs in pipeline1 in Phase 3

Drug	Indication	Stage
Elafibranor + Placebo	Nonalcoholic Steatohepatitis (NASH) With Fibrosis	Phase 3
VS-01 on top of SOC	Acute-On-Chronic Liver Failure	Phase 2
elafibranor 120mg + Placebo	Non-Alcoholic Fatty Liver	Phase 2
GFT505 80mg + Placebo	Impaired Glucose Tolerance	Phase 2
GFT505 80mg + Placebo	Atherogenic Dyslipidaemia	Phase 2

Opportunities

Elafibranor's potential approval in PBC offers a near-term path to significant revenue in an underserved market.

The NIS4® diagnostic is well-positioned to capture share in the rapidly emerging NASH screening market as therapies become available, providing a scalable, high-margin revenue stream.

Risk Factors

Intense competition in both the PBC therapeutic space and the NASH diagnostic market poses commercial threats.

Regulatory hurdles remain for elafibranor, and the company's financial runway requires careful management to reach key value inflection points without dilution.

Competitive Landscape

In PBC, Genfit faces direct competition from newly approved seladelpar (CymaBay) and established Ocaliva (Intercept). In NASH diagnostics, it competes with large labs (LabCorp, Quest) and other biotechs offering non-invasive tests, where reimbursement and guideline adoption are key battlegrounds.